Light in the Hardest Times

Light Therapy for Pets with Chronic Kidney Disease

See If Luma Can Help You Cat Feel Better

Apollo

Written by: Alon Landa
Medically reviewed by: Dr. Ron Hirshberg

Reviewed: July 2026
Updated: July 2026

One in three senior cats will develop chronic kidney disease. — International Renal Interest Society

That’s not just a statistic. It’s a call to action.

Chronic Kidney Disease (CKD) creeps in slowly, stealing energy, appetite, and quality of life from our pets when they should be enjoying their golden years. Traditional treatments work hard to slow it down — but they can’t turn back the clock.

Now? We’re shining a new light on hope.

Red light therapy is emerging as a powerful, non-invasive way to help support kidney function, energy, and comfort in pets with CKD.

Understanding Chronic Kidney Disease in Pets

CKD is a progressive, heartbreaking loss of kidney function that builds over months or even years. It leads to toxin buildup, dehydration, weight loss, muscle weakness, and eventually — heartbreak.

What’s driving it? Mitochondrial dysfunction. Oxidative stress. Chronic inflammation. Gut microbiome imbalance.

Signs of CKD may include:

  • Increased thirst and urination
  • Appetite loss
  • Weight loss
  • Dehydration
  • Weakness and lethargy

Photobiomodulation (PBM) therapy — better known as red light therapy — directly targets those issues. Using specific red and near-infrared wavelengths (typically 600-800+ nm), PBM boosts energy production inside cells, reduces inflammation, and helps calm the oxidative storm that drives disease progression (Hamblin, 2017) .It’s already well known for helping musculoskeletal injuries, wound healing, and pain management. Now it’s showing promising support for CKD, too.

🐾 Every day matters. Early support can slow the slide.
👉 Book a Free Consultation with a Clinician →

How Luma Helps Pets with CKD

The MedcoVet Luma delivers clinically relevant wavelengths — IR 850 nm, Red 635 nm — directly to areas where they can stimulate healing and energy production.

With Luma, pet parents can:

  • Stimulate mitochondrial ATP production to energize struggling cells (Hamblin, 2018)
  • Reduce inflammation around the kidneys and systemically
  • Combat oxidative stress and cell damage
  • Potentially support better hydration, appetite, and vitality

Luma makes advanced, hospital-grade therapy accessible from your living room. No stress. No drugs. No side effects.

🐾 Give your pet a boost from the inside out.
👉 See if Luma is a Fit →

Luma CKD Treatment is Backed by Research

Cream-colored Siamese cat lounging on a dark blue couch near a lit fireplace, with a fluffy beige pillow on the left.

Suits

“The Luma has been instrumental in helping Suits maintain excellent kidney function. Before we started treatment she was urinating 5-6 times per day and had a diluted specific gravity. We have been using the Luma for 18 months on 15 designated areas at 1 minute per area (every other day) Now she’s consistently urinating 2 times per day and her specific gravity has improved as well as her creatinine value.” -Traceé L. Harris

This isn’t wishful thinking. It’s science, meeting heart.

Studies show PBM therapy can:

  • 🔋 Increase cellular energy (ATP) production
  • 🔥 Reduce oxidative stress and inflammatory markers
  • 👍 Improve appetite and activity in pets with CKD
  • 🫀 Stabilize key blood values like BUN and creatinine

A pilot study presented at ASLMS showed 10 of 12 pets with late-stage CKD survived over a year after PBM therapy — with “very good to excellent” quality of life (PBM and CKD 2023).

Ongoing clinical studies using MedcoVet’s Luma are showing similar promise: over 65% of pet parents report visible improvements in energy and appetite after just a few weeks (PBM and CKD 2024).

We’re also proud to be partnering with Dr. Ronald E. Hirschberg, DVM, in an ongoing CKD-focused clinical study. Dr. Hirschberg, a pioneer in veterinary PBM therapy, has served as the medical director of Brockton Animal Hospital in Massachusetts for over 30 years. His expertise in surgery, internal medicine, and light therapy has shaped international protocols and advanced the role of PBM in treating chronic conditions like CKD. Learn more about the study here or visit his website at pbmdvm.com.

🐾 The earlier you start, the more you can help.
👉 Speak to a clinician about starting Luma

Tae Waa

“We have been using the Luma for Tae waa to help with chronic kidney disease for the past 6 months, and he has shown significant improvement in his kidney disease related symptoms since then. He is more energetic overall, has been eating better, and maintains better hydration. His overall condition is much more stable than when we started with the Luma. I have also found the Luma can help with other ailments such as constipation and wound healing, and my vet has indicated that the Luma can be used for a range of conditions and symptoms including in combination with other treatments. If there is a use case for your cat’s condition with photobiomodulation I would highly recommend looking into the Luma as a possible method of treatment.” – -Derek Robins

What the Research Says

  • Mitochondrial Support: PBM boosts mitochondrial energy output, crucial for kidney health (Hamblin, 2011).
  • Inflammation Modulation: PBM reduces damaging cytokines and promotes healing (Hamblin, 2017).
  • Pilot Study Success: 10 of 12 pets lived an extra year with better life quality when PBM was added (PBM and CKD 2023).
  • Current Clinical Trials: Early data on Luma shows improved appetite, energy, and lab stability (PBM and CKD 2024).

Safe, Soothing, and Designed for At-Home Use

MedcoVet Cat - Olivia Henderson

Olivia

“Overall, the treatment is easy. Olivia has gained two pounds while using this treatment. She still has significant kidney disease, but I feel like her quality of life is good, thanks to this treatment.”
-Hannah Henderson

Luma isn’t just powerful. It’s gentle, safe, and simple.

  • 🔹 Non-invasive, drug-free
  • 🔹 Easy to use at home in minutes
  • 🔹 No known side effects
  • 🔹 Vet-recommended as an adjunct to standard CKD care

Your pet deserves every chance to feel better — today, and tomorrow.
🐾 Learn How to Use Luma for Your Pet →

Real Stories: Pets Who Found Relief with Luma

Categories
1-3 of 3 results
  • Olivia Henderson

    “Overall, the treatment is easy. Sometimes she is grumbly about certain points on her body, so I do what I…”

  • Suits

    “The Luma has been instrumental in helping Suits maintain excellent kidney function. Before we started treatment she was urinating 5-6…”

  • Apollo

    “The Luma has made such a drastic difference for our cat, Apollo. Since beginning his treatment, Apollo has become more…”

Every story is a reminder: there’s light even when things feel dark.

Try Luma for Your Pet

CKD is a hard diagnosis. But it doesn’t have to mean giving up hope.

With Luma, you’re giving your pet an extra boost to feel better, live brighter, and stay by your side a little longer.

Let’s find out what’s possible.

Clinical Citations

  • Effects of low-level light therapy on streptozotocin-induced diabetic kidney.

    By Lim et al.

    • 2010

    • Journal: J Photochem Photobiol B

    Abstract:

    One Sentence Outcome:Rat diabetic-kidney study showing reductions in BUN/creatinine and oxidative injury markers.

    Study Parameters:LED phototherapy

    Device Parameters: Wavelength nm: 670; Irradiance: 0.035; Fluence J/cm2: 10.5; Time sec: 300; Sessions: 70

    Evidence Level:Animal Study

    Study Type: Rat

    Outcome Direction: ↑cytochrome oxidase activity, ↑cytochrome oxidase expression, ↓serum BUN, ↓serum creatinine, ↓BUN/creatinine ratio, ↓8-hydroxy-2′-deoxyguanosine in kidney; ; “LLLT may be broadly applicable to ameliorate kidney complications induced by diabetes that disrupt antioxidant defense mechanisms.”

  • Low-level laser therapy decreases renal interstitial fibrosis.

    By Oliveira et al.

    • 2012

    • Journal: Photomed Laser Surg

    Abstract:

    One Sentence Outcome:Rat renal-fibrosis study supporting PBM effects on renal tissue remodeling/fibrosis.

    Study Parameters:UUO –> renal interstitial fibrosis

    Device Parameters: Wavelength nm: 780; Power mW: 30; Irradiance: 0.75; Fluence J/cm2: 22.5; Area: 4 mm2; Time sec: 270; Sessions: 1

    Evidence Level:Animal Study

    Study Type: Rat

    Outcome Direction: “For the first time, we showed that LLLT had a protective effect regarding renal interstitial fibrosis. It is conceivable that by attenuating inflammation, LLLT can prevent tubular activation and transdifferentiation, which are the two processes that mainly drive the renal fibrosis of the UUO model.”; ; Note: See comment&reply of this paper. They discuss the mechanism a little bit.

  • Low-level laser therapy improves crescentic glomerulonephritis in rats.

    By Yamata et al.

    • 2013

    • Journal: Lasers Med Sci

    Abstract:

    One Sentence Outcome:Rat glomerulonephritis study supporting PBM effects on renal inflammatory injury.

    Study Parameters:Glomerulonephritis; (crescentic)

    Device Parameters: Wavelength nm: 830; Irradiance: 0.88; Energy J: 500; Fluence J/cm2: 220; Area: 2.27 cm2; Time sec: 250; Sessions: 14

    Evidence Level:Animal Study

    Study Type: Rat

    Outcome Direction: “Histological observations indicated that LLLT suppressed crescent formation and infiltration of ED1+ macrophages and CD8+ lymphocytes into the glomeruli. LLLT attenuated the levels of IL-1β and TNF-α messenger RNA in the renal cortex.; ; Externally directed LLLT suppresses the activity of rat anti-GBM crescentic glomerulonephritis in rats. LLLT has the potential to be used for direct treatment of glomerulonephritis.”; ; Star: Parameters were well reported.

  • Effect of photobiomodulation on ischemia/reperfusion-induced renal damage in diabetic rats.

    By Asghari et al.

    • 2016

    • Journal: Lasers Med Sci

    Abstract:

    One Sentence Outcome:Diabetic-rat renal ischemia/reperfusion study supporting reduced oxidative stress, BUN, and creatinine.

    Study Parameters:Diabetic rats

    Device Parameters: Wavelength nm: 685; Power mW: 15; Fluence J/cm2: 3.2; Area: 0.28 cm2; Sessions: 3

    Evidence Level:Animal Study

    Study Type: Rat

    Outcome Direction: Effects of photobiomodulation: ; ; ↑GSH, ↑SOD, ↑CAT; ↓BUN, ↓MDA, ↓MPO, ↓NO, ↓creatinine, ↓histological injury ; ; “The results of present investigation revealed that PBM attenuated kidney damage induced by renal IR in diabetic rats.”

  • Mesenchymal Stem Cells Synergize with 635, 532, and 405 nm Laser Wavelengths in Renal Fibrosis: A Pilot Study.

    By O’Connor et al.

    • 2016

    • Journal: Photomed Laser Surg

    Abstract:

    One Sentence Outcome:Mouse renal-fibrosis pilot supporting PBM interaction with mitochondrial and anti-fibrotic repair pathways.

    Study Parameters:Blue light ; Green light ; ; Wavelength comparison

    Device Parameters: Wavelength nm: 405 532 635

    Evidence Level:Animal Study

    Study Type: Mouse

    Outcome Direction: “Wavelengths 405, 532, and 635 nm all significantly synergized with MSC to enhance mitochondrial activity and reduce apoptosis. Proliferative activity was observed in the renal cortices following combined treatment with the 532 nm laser and MSC; endothelial proliferation increased in response to the 635 nm laser alone and to the combined effects of MSC and the 405 nm wavelength. Reductions of transforming growth factor-β were observed with 532 nm alone and when combined with MSC.”

  • Laser therapy in metabolic syndrome-related kidney injury.

    By Ucero et al.

    • 2013

    • Journal: Photochem Photobiol

    Abstract: λ = 785 nm (770-795); “Transcutaneous therapeutic LLLT of kidney tissue”

    One Sentence Outcome:Rat metabolic-syndrome kidney injury study supporting effects on renal function and blood pressure.

    Study Parameters:Kidney injury

    Device Parameters: Wavelength nm: 785

    Evidence Level:Animal Study

    Study Type: Rat

    Outcome Direction: ↓ blood pressure; ↑ glomerular filtration rate

  • Review of light parameters and photobiomodulation efficacy: dive into complexity.

    By Zein et al.

    • 2018

    • Journal: J Biomed Opt

    Abstract:

    One Sentence Outcome:Page-cited PBM parameter review supporting dose/wavelength/irradiance considerations for PBM efficacy.

    Study Parameters:

    Device Parameters: Wavelength nm: “Photobiomodulation (PBM) therapy, previously known as low-level laser therapy, was discovered more than 50 years ago, yet there is still no agreement on the parameters and protocols for its clinical application. Some groups have recommended the use of a power density less than 100 mW/cm2 and an energy density of 4 to 10 J/cm2 at the level of the target tissue. Others recommend as much as 50 J/cm2 at the tissue surface. The wide range of parameters that can be applied (wavelength, energy, fluence, power, irradiance, pulse mode, treatment duration, and repetition) in some cases has led to contradictory results. In our review, we attempt to evaluate the range of effective and ineffective parameters in PBM. Studies in vitro with cultured cells or in vivo with different tissues were divided into those with higher numbers of mitochondria (muscle, brain, heart, nerve) or lower numbers of mitochondria (skin, tendon, cartilage). Graphs were plotted of energy density against power density. Although the results showed a high degree of variability, cells/tissues with high numbers of mitochondria tended to respond to lower doses of light than those with lower number of mitochondria. Ineffective studies in cells with high mitochondrial activity appeared to be more often due to over-dosing than to under-dosing.”

    Evidence Level:Narrative Review

    Study Type: Review

    Outcome Direction:

  • Chronic Kidney Disease Trial in Cats – Photobiomodulation and Red Light Therapy Update

    By Hirschberg RE

    • 2023

    • Journal: PBMDVM clinical trial update

    Abstract: Clinical update describing launch/enrollment of an in-home owner-applied photobiomodulation trial for feline CKD.

    One Sentence Outcome:Veterinary CKD trial update supporting the page’s claim that PBM is being studied in cats with CKD.

    Study Parameters:Page reports an in-home, owner-applied PBM study for feline CKD with staging requirements.

    Device Parameters: Home-applied red light therapy / photobiomodulation

    Evidence Level:Clinical report / ongoing study

    Study Type: Veterinary clinical trial update

    Outcome Direction: Ongoing trial/recruitment update; supports page citation for veterinary CKD PBM study context.

  • Clinical Study Using Laser Therapy (Photobiomodulation) to Treat Chronic Kidney Disease

    By Hirschberg RE

    • 2024

    • Journal: PBMDVM clinical study update

    Abstract: Interim report describing veterinary PBM use for canine/feline CKD, including appetite/activity reports and renal biochemistry monitoring.

    One Sentence Outcome:Interim veterinary CKD report supporting appetite, activity, and renal-parameter claims on the CKD page.

    Study Parameters:Reports 29 enrolled patients, 23 active after exclusions, and owner-reported appetite/activity changes.

    Device Parameters: At-home red light therapy / PBM

    Evidence Level:Clinical report / ongoing study

    Study Type: Veterinary clinical study interim report

    Outcome Direction: Early/interim data suggests owner-reported appetite/activity improvement and stable or improved renal parameters in some patients.

  • Therapeutic Potential of Photobiomodulation for Chronic Kidney Disease

    By Bian et al.

    • 2022

    • Journal: Int J Mol Sci

    Abstract:

    One Sentence Outcome:Direct CKD review supporting PBM as a potential therapeutic adjunct for kidney disease mechanisms.

    Study Parameters:

    Device Parameters: Wavelength nm: “Preliminary studies suggest the benefits of PBM in multiple diseases, including CKD. Hence, this review will provide a concise summary of the underlying action mechanisms of PBM and its potential therapeutic effects on CKD. Based on the findings, PBM may represent a novel, non-invasive and non-pharmacological therapy for CKD, although more studies are necessary before PBM can be widely recommended.”

    Evidence Level:Narrative Review

    Study Type: Review

    Outcome Direction:

About the Author
Alon Landa is the CEO and co-founder of MedcoVet, a leader in at-home red light therapy for pets. With over 20 years of experience in medical technology and firsthand involvement in developing the Luma, Alon combines deep technical knowledge with a passion for improving pet health. He regularly collaborates with veterinarians and pet parents to advance photobiomodulation (PBM) care at home.
 📍 Based in Boston, MA
📖Read more from Alon here

Senior male doctor in a white coat with a stethoscope around his neck, looking thoughtful.

About the Medical Reviewer
Dr. Ronald Hirschberg has been the long term hospital director of the Brockton Animal Hospital, in Brockton, Massachusetts. He came to the hospital after graduating from The Ohio State University College of Veterinary Medicine, and served as medical director for more than 30 years. During his tenure, Dr. Hirschberg developed the facility into a full service hospital emphasizing surgery as well as medicine. His areas of interest include orthopedics, ophthalmology, dermatology, and Photobiomodulation or Red Light Therapy (previously known as Low Level Laser Therapy).

He is a recognized authority on Photobiomodulation and its application in companion animal medicine. His treatment protocols have been adopted for use by several light device practitioners and manufacturers. Dr. Hirschberg was invited to sit on a multi-day task force at the World Association of Photobiomodulation (WALT) international meeting in Nice, France in 2018 in an effort to create standardized protocols for several medical conditions.

Dr. Hircshberg is the author of PBMDVM a site dedicated to educating both clinicians and pet parents about the benefits of photobiomodulation in animal health.

📍 Based in Newton, MA
📖Read more from Dr Ron here